Shares of Bavarian Nordic surged after the Danish biotechnology company reported fourth-quarter revenue that exceeded market expectations, driven by strong demand for travel vaccines. The company's travel vaccine portfolio, including its RabAvert rabies vaccine, saw a notable increase in sales as global travel resumed post-pandemic.

The revenue beat comes as travelers increasingly seek protection against diseases like rabies and yellow fever, particularly in regions where such illnesses remain prevalent. Bavarian Nordic's travel vaccine segment has become a significant contributor to its overall financial performance, with the company benefiting from both increased travel activity and heightened awareness of preventive healthcare.

This positive earnings surprise reflects the company's successful positioning in the travel medicine market, where it has established itself as a key supplier of vaccines for international travelers. The strong quarterly results suggest continued momentum for Bavarian Nordic's travel vaccine business as global mobility patterns normalize and vaccination rates increase among travelers.